Skip to content

Do Discounted Vouchers for Medical Cannabis Reduce Opioid Use in Adults With Pain

CompletedNot applicableNCT04495725
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

This study will examine how discounted vouchers for medical cannabis use affects opioid analgesic use in adults with chronic pain. Our study findings will have critically important implications to shape clinical care and medical cannabis policies.

Study details

Official title
Do Discounted Vouchers for Medical Cannabis Reduce Opioid Use in Adults With Pain: A Randomized Controlled Trial (The ReLeaf-V Study)
Conditions
Interventions
  • Other: Discounted Vouchers for Medical Cannabis Soft-Gel Capsule Products
Sponsor
Vireo Health
Start date
2020-10-06
Primary completion
2024-03-13
Sex
All
Age range
from 18 Years to 99 Years
Results posted
No results posted in this snapshot
Countries
United States
Total sites listed
1

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. \>18 years old 2. English or Spanish fluency 3. active certification for medical cannabis 4. intends to have a soft-gel capsule product dispensed at Vireo Health 5. medical cannabis qualifying conditions or complications of (a) chronic pain, or (b) pain that degrades health and functional capability as an alternative to opioid use or substance use disorder or (c) severe or chronic pain 6. joint or neuropathic pain 7. current severe pain 8. dispensed opioids analgesics within the last 60 days To maintain the integrity of the study, we do not disclose all inclusion criteria to potential participants. Exclusion Criteria: 1. inability to provide informed consent 2. inability to complete study visits over 14 weeks 3. terminal illness 4. current or prior psychotic disorder 5. current or prior buprenorphine or methadone treatment for opioid use disorder 6. NYS medical marijuana prescriber does not approve changes to product and dosing recommendations listed on the participant's certification form 7. Allergy to tapioca or coconut 8. currently pregnant, planning to become pregnant within the next 3 months, or breastfeeding 9. a condition that is considered by a pharmacist or medical provider to be a clinical contraindication to medical cannabis use (e.g. unstable cardiac arrhythmia or specific drug-drug interaction)

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04495725